NCCN Adds Nirogacestat to Guidelines for Patients With Soft

The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.

Related Keywords

United States , Americans , Richard Pazdur , Office Of Oncologic Diseases , National Comprehensive Cancer Network , Oncology Center , Oncologic Diseases , Drug Evaluation , Practice Guidelines , Soft Tissue Sarcoma Guidelines , Version 3 2023 , Preferred , Ategory 1 Recommendation , Nirogacestat , Ogsiveo , Phase 3 Defi Trial Nct03785964 ,